Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 720 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Disease Clear all
Terminated Phase 2 Interventional Results available

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCT04437368
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
GT005
Drug
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Not applicable Interventional

Evaluation of an Investigational Lubricant Eye Drop on Lipid Layer Thickness

NCT01066988
View directory record Official record
Conditions
Dry Eye
Interventions
ORB Ocular Emulsion, SootheXP Emollient (Lubricant) Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 2 Interventional

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye

NCT01558999
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
High concentration SI-614, Low concentration SI-614, Vehicle
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

NCT02553772
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop, Carboxymethylcellulose Sodium 0.5%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
10
States / cities
Azusa, California • Burbank, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 2 Interventional

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

NCT06370039
View directory record Official record
Conditions
Dry Eye Disease
Interventions
INV-102, Vehicle
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rush, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Patients With Blepharitis and Facial Rosacea

NCT00560703
View directory record Official record
Conditions
Blepharitis, Meibomianitis, Dry Eye
Interventions
COL-101 (doxycycline, USP) capsules, placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Naples, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 4 Interventional

Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase

NCT00520260
View directory record Official record
Conditions
Dry Eye Disease, Ocular Comfort
Interventions
bromfenac, ketorolac
Drug
Lead sponsor
Florida Eye Microsurgical Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization

NCT05322148
View directory record Official record
Conditions
Dry Eye
Interventions
Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Hemet, California • Laguna Hills, California • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 4, 2026, 4:07 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye

NCT07490535
View directory record Official record
Conditions
Ocular Surface Disease, Dry Eye Syndrome (DES)
Interventions
(Xiidra®) Lifitegrast Ophthalmic Solution 5.0%
Drug
Lead sponsor
Pittsburgh Research Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Sewickley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 4, 2026, 4:07 AM EDT
Recruiting Phase 4 Interventional

Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease

NCT07676084
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

NCT04567329
View directory record Official record
Conditions
Dry Eye Disease
Interventions
NOV03, Saline Solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
35
States / cities
Phoenix, Arizona • Garden Grove, California • Hemet, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 4, 2026, 4:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Microbiome

NCT02298881
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 4, 2026, 4:07 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers

NCT01317030
View directory record Official record
Conditions
Dry Eye
Interventions
Contact Lens Wear, Non-Contact Lens Wear
Device · Other
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

NCT04572841
View directory record Official record
Conditions
Sjögren's Syndrome, Sjogren's Syndrome
Interventions
SAR441344, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
DeBary, Florida • Duncansville, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

NCT06544694
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial Tears
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Louisville, Kentucky • Garner, North Carolina • Leland, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 4, 2026, 4:07 AM EDT
Recruiting Phase 1 Interventional

Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

NCT06392711
View directory record Official record
Conditions
Xerostomia, Graft-versus-host-disease, Sjogren's Disease
Interventions
Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Dry Eye Syndrome on Metrics of Low Contrast Vision Before and After Meibomian Gland Expression

NCT05713981
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Meibomian gland (MG) expression
Procedure
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 4, 2026, 4:07 AM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

NCT05586152
View directory record Official record
Conditions
Dry Eye Disease
Interventions
INV-102, Vehicle
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rush, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 4:07 AM EDT
Recruiting Phase 4 Interventional

Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment

NCT07606625
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
Varenicline 0.03Mg/Spray Nasal Soln
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 4, 2026, 4:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diurnal Variation in Tear Osmolarity

NCT01321424
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Not listed
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
6
States / cities
Fairfield, Connecticut • Lynbrook, New York • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 4, 2026, 4:07 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

NCT03162783
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
ADX-102 Ophthalmic Solution (0.5%), ADX-102 Ophthalmic Solution (0.1%), ADX-102 Ophthalmic Lipid Solution (0.5%)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 4, 2026, 4:07 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Sjogren's Mini-Pill Oral and Gut Microbiome Study

NCT07732582
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Mini-Pill
Device
Lead sponsor
Tufts University
Other
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 4, 2026, 4:07 AM EDT